Oseltamivir: Difference between revisions

(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: Tamiflu ==Adult Dosing== ===Influenza==== *75mg PO BID x 5 days ==Pediatric Do...")
 
No edit summary
Line 6: Line 6:


==Adult Dosing==
==Adult Dosing==
===[[Influenza]]====
===[[Influenza]]===
*75mg PO BID x 5 days
*75mg PO BID x 5 days


==Pediatric Dosing==
==Pediatric Dosing==
===[[Influenza]]====
===[[Influenza]]===
*'''Age <1 year:''' 3mg/kg PO BID x 5 days
*'''Age <1 year:''' 3mg/kg PO BID x 5 days
*'''<15kg:''' 30mg PO BID x 5 days
*'''<15kg:''' 30mg PO BID x 5 days

Revision as of 22:16, 26 April 2016

Administration

  • Type:
  • Dosage Forms:
  • Routes of Administration:
  • Common Trade Names: Tamiflu

Adult Dosing

Influenza

  • 75mg PO BID x 5 days

Pediatric Dosing

Influenza

  • Age <1 year: 3mg/kg PO BID x 5 days
  • <15kg: 30mg PO BID x 5 days
  • 15-23kg: 45mg PO BID x 5 days
  • 24-40kg: 60mg PO BID x5d
  • Adult: 75mg PO BID x 5 days

Special Populations

Renal Dosing

  • Adult:
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:

Mechanism of Action

Comments

  • Influenza
    • Shortens duration of illness by 16.8 hrs while NNTH (number needed to harm) was 28 in regards to causing n/v, HA, and renal and psych syndromes[1]
    • Greatest benefit if within 48hrs of symptom onset[2]
      • However, may be beneficial up to 4-5 days, including in pregnant patients
      • Early treatment of hospitalized pts can reduce death

See Also

References

  1. Jefferson T, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2545.
  2. CDC Guidelines. 2015-2016. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm